|
2015
|
Invention
|
Bisaryl (thio)morpholine derivatives as s1p modulators. Described are compounds that are modulato... |
|
2013
|
Invention
|
Heterocyclic compounds with affinity to muscarinic receptors. The present invention relates to he... |
|
|
Invention
|
Fused heterocyclic derivatives as s1p modulators. The present invention relates to a fused hetero... |
|
|
Invention
|
Fused heterocyclic derivatives as s1p modulators. This invention relates to new fused heterocycli... |
|
2011
|
Invention
|
Method for determining the risk of developing a neurological disease.
Methods and kits are provi... |
|
|
Invention
|
Bisaryl (thio)morpholine derivatives as s1p modulators. The present invention relates to bisaryl ... |
|
|
Invention
|
Spiro-cyclic amine derivatives as s1p modulators. The present invention relates spiro- cyclic ami... |
|
2010
|
Invention
|
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and... |
|
|
Invention
|
Combination preparations comprising slv308 and a dopamine agonist. A composition containing SLV30... |
|
2009
|
Invention
|
Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability.
This... |
|
|
Invention
|
Spiro azepane-oxazolidinones as kv1.3 potassium channel blockers. This invention concerns spiro a... |
|
2008
|
Invention
|
N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs. Embodiments of the invention rela... |
|
|
Invention
|
Method for determining the risk of developing a neurological disease. Methods and kits are provid... |
|
|
Invention
|
1 antagonism and serotonin reuptake inhibition. 1 antagonism and serotonin reuptake inhibition, p... |
|
2007
|
Invention
|
1 antagonism and acetylcholinesterase inhibition. 1 antagonism and cholinesterase inhibition is a... |
|
|
Invention
|
Embedded micellar nanoparticles. The present invention relates to a thermostable solid compositio... |
|
|
Invention
|
1 h-imidazole derivatives as cannabinoid receptor modulators. The invention relates to a group of... |
|
|
Invention
|
Combination preparations comprising bifeprunox and a dopamine agonist. The present invention rela... |
|
|
Invention
|
1 receptor antagonists. 2 receptor subtype selectivity, to methods for the preparation of these c... |
|
2006
|
Invention
|
Glucuronate salt of a piperazine compound. The present invention provides a salt form, and compos... |
|
|
Invention
|
Salicylate and gentisate salts of a piperazine compound. The present invention provides salt form... |
|
|
Invention
|
Sustained-release formulation and uses thereof. The present invention provides sustained-release ... |
|
|
Invention
|
1h-imidazole derivatives as cannabinoid cb2 receptor modulators. 2 receptors are involved.
The c... |
|
|
Invention
|
[1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone ox... |
|
2005
|
Invention
|
1-antagonistic activity. 1) receptor antagonists with utility for the treatment of diseases conne... |
|
|
Invention
|
2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity. The present... |
|
|
Invention
|
3 antagonistic activity. 3 receptor antagonists, to methods for the preparation of these compound... |
|
|
Invention
|
Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1-benzopyran-2-one.
The present inv... |
|
|
Invention
|
Polynucleotides and expression system of a novel human g-protein coupled receptor. The present in... |
|
|
Invention
|
Binding assay employing igs4, a human g-protein coupled neuromedin receptor. The present inventio... |
|
|
Invention
|
2 receptor and the serotonin reuptake site. The invention relates to the novel mesylate of a phen... |
|
|
Invention
|
1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain.
The invention r... |
|
|
Invention
|
Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and... |
|
2004
|
Invention
|
1h-imidazole derivatives as cannabinoid receptor modulators. The invention relates to a group of ... |
|
|
Invention
|
Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-... |
|
|
Invention
|
Solid salts of benzazepine compounds and pharmaceutical compositions containing them.
and in whi... |
|
|
Invention
|
1-antagonistic, agonistic or partial agonistic activity. Computer game systems respond to the spa... |
|
|
Invention
|
Neurotensin active 2,3,diaryl-pyrazolidine derivatives. The invention relates to a group of novel... |
|
|
Invention
|
Antibodies immunospecific for a novel human g-protein coupled receptor family. The present invent... |
|
2003
|
Invention
|
4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity.
|
|
2002
|
Invention
|
Human g-protein coupled receptor. The present invention relates to novel identified polynucleotid... |
